Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.41 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (somatotrophs) | 0.10 |
| chemistry Open Targets | compounds already reach it: mofarotene, alitretinoin, irx-4204 +3 | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 2 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 0626
Sealed predictions
- RXRG in dopamine neurons, braak-0.17 (p 0.670) → -0.01 (p 0.982)receipt 0632
Swarm cases
receipt 0632: RXRG in dopamine neurons, braak
- power
- full sample -0.09 (p 0.728, n 18), 95% CI -0.53 to +0.40. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.03 (p 0.894, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.17 (p 0.509, n 18). could be the mix.
- skeptic
- leave-one-out range -0.22 to +0.01, sign flips 2; without severely affected donors -0.09 (p 0.728, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RXRG in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts